Clinical Study On Mongolian Medicine Heisuga-25 In The Treatment Of Huo Sa Recovery Period

Objective:In this study,the clinical efficacy of Mongolian medicine Heisuga-25 in the treatment of ischemic stroke(Huo Sa)was evaluated before and after taking.Mongolian medicine Heisuga-25,and the levels of vascular endothelial growth factor and brain-derived neurotrophic factor in serum were detected.The clinical efficacy of Mongolian medicine Heisuga-25 in the treatment of ischemic stroke(Huo Sa)was judged,and its safety and reliability were evaluated,so as to provide scientific clinical basis for Mongolian medicine in the treatment of ischemic stroke(Huo Sa)in the future.Methods:The experimental cases were 100 outpatients who met the inclusion criteria of the experiment from December 2020 to December 2021 in the encephalopathy department of the Affiliated Hospital of Inner Mongolia Minzu University.They were randomly divided into experimental group and control group,50 cases in each group.Both groups were given conventional western medicine treatment;Aspirin Enteric-coated Tablets were orally administered 100 mg in the morning and Atorvastatin Calcium Tablets were orally administered 20 mg before sleep.On this basis,the patients in the experimental group were given Mongolian medicine Heisuga-25 1.5 g in the morning and evening.Four weeks after treatment,the patients were assessed with neurological deficit scale before treatment and four weeks after treatment,including National Institutes of Health Stroke Scale(NIHSS),Activities of Daily Living Scale(ADL)and Mongolian Medicine Syndrome Score Table.The levels of VEGF and BDNF in serum were detected before treatment and four weeks after treatment,and the blood and urine routine,liver and kidney function,coagulation function,homocysteine,blood lipids,ECG and other safety tests were carried out.The data were collected and analyzed by SPSS26.0 software.Results:1.There was no significant difference in the levels of serum vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF)between the experimental group and the control group before medication(P>0.05),2.The experimental group compared with the control group,the experimental group after treatment in serum vascular endothelial growth factor(VEGF)level decreased,the difference was statistically significant(P<0.05).3.Compared with the control group,the serum brain-derived neurotrophic factor(BDNF)level in the experimental group was significantly increased after treatment,and the difference was statistically significant(P<0.05).4.Compared with the control group,the scores of neurological deficit scale(National Institutes of Health Stroke Scale,NIHSS)and Mongolian medicine Sa disease symptom score scale in the experimental group decreased,and the scores of activities of daily living(ADL)scale increased,the difference was statistically significant(P<0.05).5.By observing the two groups of patients with blood,urine routine,liver and kidney function,coagulation,blood lipids and electrocardiogram safety inspection,the difference was not statistically significant(P>0.05),no obvious abnormal changes and other side effects.Conclusion:1.Mongolian medicine Heisuga-25 has a good clinical effect in the treatment of ischemic stroke recovery(Huo Sa).2.Mongolian medicine Heisuga-25 can promote the prognosis of patients with ischemic stroke by regulating the levels of vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF).3.Mongolian medicine Heisuga-25 is safe and effective in patients with ischemic stroke recovery(Huo Sa).